Bioject Enters Into Distribution Agreement With FlashMed Inc. In Ecuador
TIGARD, Ore., Oct. 30, 2013
TIGARD, Ore., Oct. 30, 2013 /PRNewswire/ --Bioject Medical Technologies Inc.
(OTC Pink: BJCT), a leading developer and manufacturer of needle-free
injection technology, today announced that it has entered into a distribution
agreement with FlashMed Inc. a medical supply company based in Quito, Ecuador.
FlashMed will be the exclusive distributor of the Biojector® 2000 needle-free
injection system and the Bioject® ZetaJet™ portable injector products in
"We are very pleased to have entered into this agreement with FlashMed and we
look forward to providing access to our advanced delivery systems to
clinicians and patients in Ecuador," said Mark Logomasini, President and CEO
of Bioject. "This is Bioject's first entry into South America with our
expectation that we will continue to add distribution in the area. FlashMed is
a strong, capable partner and this furthers our ability to meet the increasing
global demand for needle-free injection systems. Since the beginning of 2013
Bioject has expanded its network into Asia, Australia, the Philippines, the
Middle East, and Africa with top tier distributors in all of these regions. In
addition to selling commercial devices, these groups are driving innovation
for the next important advances in Bioject technology."
About Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a
developer and manufacturer of needle-free injection therapy systems (NFITS).
NFITS works by forcing medication at high speed through a tiny orifice held
against the skin. This creates a fine stream of high-pressure fluid able to
penetrate skin and deposit medication in the tissue beneath. To meet global
demand for needle free injection technologies, Bioject is focused on
developing mutually beneficial agreements with leading pharmaceutical,
biotechnology, and veterinary companies, as well as research, global health
and government organizations.
Readers and potential investors are cautioned that an investment in the
Bioject's securities involve an EXTREMELY high degree of risk. Such risks
include, without limitation, the risk that the distribution agreement will not
be successful due to the time required in obtaining government clearances and
the risk that the Company may be unable to comply with the extensive
government regulations applicable to the international business. Bioject (OTC
Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find
Real-Time quotes and market information for the Company on
For more information about Bioject, visit www.bioject.com
SOURCE Bioject Medical Technologies Inc.
Contact: Bioject Medical Technologies Inc., Mark Logomasini, President and
CEO, 503-692-8001; Christine Farrell, Vice President of Finance, 503-692-8001
Press spacebar to pause and continue. Press esc to stop.